Vaishali Pharma Limited (NSE:VAISHALI)

Market Cap	913.23M -37.5%
Revenue (ttm)	1.14B +15.0%
Net Income	-5.09M
EPS	-0.05
Shares Out	130.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,920
Average Volume	104,238
Open	7.05
Previous Close	6.99
Day's Range	6.92 - 7.05
52-Week Range	4.75 - 13.59
Beta	0.44
RSI	46.07
Earnings Date	May 29, 2026

About Vaishali Pharma

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 27
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VAISHALI

Financial Performance

In fiscal year 2025, Vaishali Pharma's revenue was 990.26 million, an increase of 14.77% compared to the previous year's 862.80 million. Earnings were 8.17 million, an increase of 13.70%.